We have a Monster Pick Coming. Subscribe Right Now!<\/strong><\/span>
\n [newsletter_form]<\/strong><\/span><\/p>\n
Pharmacyte Biotech Inc (OTCMKTS:PMCB) closed at an intra-day high on breaking news that its encapsulation facility for pancreatic cancer therapy was deemed suitable by the Thai FDA. This is a very bullish development. The stock has climbed past its highs set in mid-March of $0.074 and current trading at $0.077. It has developed a higher high and poised for more gains from current levels and should easily climb higher from current levels.<\/p>\n
The encapsulation facility in Thailand that will be used to encapsulate the live cells used for PharmaCyte\u2019s pancreatic cancer therapy has recently been inspected by the Food and Drug Administration of Thailand. Thai FDA stated through a report that, \u201cThe facility is built according to the pre-approved floor plan and is now deemed suitable for the manufacture of pharmaceutical products.\u201d<\/p>\n
The Chief Executive Officer stated, \u201cWe are very pleased that our partner, Austrianova, has received a positive opinion from the Thai FDA for Austrianova\u2019s live-cell encapsulation facility. This is an important milestone in the development of PharmaCyte\u2019s treatment for pancreatic cancer and a pre-requisite for our upcoming pancreatic cancer clinical trial.\u201d<\/p>\n
On April 6th PMCB announced it has changed its clinical trial design. This means that the actual date for the clinical trial is unknown at this point. While the new trial design offers PMCB a much better shot at success with FDA and EMA approval, it has also been an exercise in patience for the company’s leadership and its shareholders.<\/p>\n
PMCB just released its financial information with the SEC according to a recent filing. PMCB is set to launch a new clinical trial sometime in 2016 for pancreatic cancer patients. There is a huge unmet medical need and people will welcome a solution that could potentially increase the lifespan for late stage pancreatic patients. If the clinical trial is successful, PMCB will be gaining more than just 50% to investors and likely cause the company to increase in value significantly and potentially be acquired by a larger pharmaceutical company.<\/p>\n
Any positive results would move PMCB into the spotlight and above other early stage biotechs who are trying to come up with a solution as well. There would be a substantial increase in the company\u2019s value and it would absolutely be able to attract major attention from large pharmaceutical companies. It would give a much needed viable option for pancreatic cancer treatment.<\/p>\n
The market size for pancreatic cancer is huge. Looking only at major developed countries, the market size should reach close to $3 billion within the next 5 years. If we look at the addressable market that in the United States only is equally impressive, which PMCB should easily be able to attain. A typical drug price for this disease is roughly between $50k and $75k per year. There are about 43,000 patients diagnosed with pancreatic cancer a year. Assuming that 60% of the patient pool would switch to PMCBs drug, the market size in the USA could be estimated at $1.25 billion to $1.8 billion. Given the market valuation is only $51 million, a successful positive trail will send shares flying through the stratosphere.<\/p>\n
![\"PMCB\"](\"https:\/\/microcapspot.com\/wp-content\/uploads\/2016\/04\/Capture-17.png\")
<\/a><\/p>\n